Bristol Meyers Squibb (BMS), manufacturers of Efavirenz (patented drug for HIV) won over the companies named Mylan Pharmaceuticals Inc. and Mylan Laboratories Ltd. that made generic version of Efavirenz that is Sustiva. The companies filed an application in court for…
Recently, the Tufts University’s Center for the Study of Drug Development (CSDD) released an interesting report revealing the dramatic shift of pharmaceutical companies from manufacturing small molecule drugs to a large number of biotechnology drugs. The report shows that in…
Year 2014 would be a big loss year for the Pharma companies because of the expiry of patents granted for some of the major medicines. It is estimated that due to the loss of IP protection, sales worth $34 billion…
South Africa could not keep up with the treatment for Drug resistant Tuberculosis (TB), which has affected thousands of people in the country. Many of the sufferers would die and the death would be horrible and slow. Not only this,…
Indian pharmaceutical companies have increased their expenditure in their research and development section by 19.7%. The purpose of this increment is not to discover new drugs but to create more cost effective generic drugs. More investment may make them a…